If navigate to the rest of our site, you will find lots of information regarding the causes and the types of female sexual disorders, a few pages dedicated to the most-known FSD treatments and useful resources on this illness.
Female Sexual Dysfunction
In the United States more women, 40 million; about 43% than men, 31% suffer from sexual dysfunction. Evidence show that most of them are aged women, because sexual dysfunction manifests after menopause, when hormone production drops and vascular conditions are more common. Younger women can also experience problems with arousal, orgasm, and satisfaction.
Intrinsa is available in Europe. The only online pharmacy where you can buy 300mcg/24h Intrinsa online is 121doc.uk.
In spite of quality scientific data, Intrinsa was not approved yet. Until Procter & Gamble develop a legitimate treatment other very effective medication is available for sale. In the meantime we strongly recommend that you try:
VIGORELLE - treatment for restoring sexual satisfaction
PROVESTRA - known as Estravil is designed to enhance female libido
1ST Congress for Sexual Health
Sydney 15 - 19 April 2007, 18th World Congress of the WAS, 1st World Congress for Sexual Health :: Achieving Health, Pleasure and Respect
This interactive workshop will define the interface between sexuality and cancer. Both cancer and its treatment have an extensive influence on sexuality, intimacy and fertility. Sexology health care professionals are often hesitant to discuss sexuality with their patients. As a result, many patients fail to receive the care and attention they deserve.
Information of the various aspects of biology, psychology, fertility, relationship and intimacy will be supplemented by information on treatment and patient care.
Workshops Registration: A registration service will be available soon to register for the workshops. Please drop a mail to email@example.com
What is Female Sexual Dysfunction?
Female sexual dysfunction or FSD, often named frigidity, describes an aversion, indifference or hostility to sexual activity, no response to sexual stimulation, an inability to achieve orgasm, or a disturbance in, or pain with sexual intercourse.
Sexual dysfunction in women cases can be subdivided into desire (lack of sexual desire), arousal (problems in becoming aroused or achieving lubrication), orgasmic and sexual pain disorders (dyspareunia and vaginismus).
Doctors and researchers give more significance to male sexual problems. Very few of them tried to analyze female sexual dysfunctions.
The main reason is the difficulty to diagnose and treat the sexual dysfunction in female cases than it is in men because of the intricacy of the female sexual response.
Intrinsa is available in pharmacies throughout the European Union
Although many perceive it as a men problem, sexual dysfunction is encountered more often in women. While men have various treatments to choose from, like Viagra, there still isn’t any “magic pill” for women. They only have high hopes for Intrinsa. This is a testosterone patch meant for a woman to wear on her abdomen. It releases a low dose of hormones that increase the sexual drive. Many companies are developing pills, creams, gels and sprays for female sexual dysfunctions. All these treatments have one thing in common: they are not approved by the FDA, so be careful of their possible side effects.
To be able to launch its testosterone patch, Intrinsa, on the market Procter & Gamble needed FDA’s approval. An FDA advisory panel analyzed the patch and decided not to approve it because of safety concerns. They voted unanimously Intrinsa needs to be submitted to more tests to find out what the long term side effects are.
Despite testing P&G could only guarantee the safety of using the Intrinsa patch for a one-year period. After that time it was unclear about how it worked.
P&G had no future plans to try again for FDA approval to market their patch, but thay have applied to the European Commission to develop and sell Intrinsa. They have received the Marketing Authorisation valid throughout the European Union in July, 28 2006. The patch is now available in pharmacies across Europe. The patch is only available on prescription after a full assessment from a doctor and only after all other forms of treatment and therapy have been explored (for example counselling, education, lubricant provision, relationship therapy etc).
Women can use only 2 patches by week, that is 1 patch every 2 or 3 days. The patch delivers 300 micrograms of testosterone / 24 hours. The transdermal patch can be used for the treatment of hypoactive sexual desire disorder (HSDD) in women with surgically induced menopause only. The treatment is not recommended for women with natural menopause, nor for women over 60 years old.
LibiGel is a once-daily transdermal testosterone gel in late-stage clinical development for the treatment of FSD, specifically HSDD.
LibiGel's formulation of bioidentical testosterone is quickly absorbed through the skin after application on the arm or shoulder, delivering testosterone to the bloodstream evenly over time in a non-invasive, painless manner.
In a Phase II clinical trial, LibiGel increased the number of successful and satisfying sexual events by 238 percent, which was statistically significant compared to baseline and placebo.
DISCLAIMER AND LIMITATION OF WARRANTY/LIABILITY
The material contained herein is not intended to replace qualified medical advice. Healthcare services should be performed by your doctor or psychiatrist/psychologist. Consult with your doctor before applying any of the treatments presented on this website.